Processa Pharmaceuticals Inc. (PCSA) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.89 (0.00% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PCSA ranks #494 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PCSA carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SCNX (Scienture Holdings Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and ADXN (Addex Therapeutics Ltd) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $5.3M). Among the 5-stock peer group, PCSA leads on earnings multiple (N/A) while PCSA leads on capital efficiency (-35.0% ROIC).
Per PCSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533743), Processa Pharmaceuticals Inc. generated $0 in revenue, -$13.6M in net income, and -$11.4M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 55.7 (BULLISH MOMENTUM)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While PCSA currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.84) and Max Pain ($1.98) forces dealer call-delta covering toward $10.76.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Processa Pharmaceuticals Inc. (PCSA) slipped 0.00% to $1.89, trading at 9% of its 52-week range ($1.04 – $10.25). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.
Kalkine report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1533743/000114036126041116/ef20084530_8k.htm
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PCSA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PCSA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Processa Pharmaceuticals Inc. (PCSA) ranks #494 by composite RQD confidence (39/100, grade D-) and #936 by equity capitalization ($5.3M). Within this direct 5-issuer industry benchmark cohort, PCSA leads on earnings valuation at N/A trailing P/E, while PCSA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with PCSA at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PCSA
ACTIVE
Processa Pharmaceuticals Inc. | D- | 39/100 | — | — | -35.0% | 0.00% | $5.3M | Benchmark Subject |
| SCNX Scienture Holdings Inc. | E | 28/100 | — | 76.8% | -35.0% | -7.74% | $5.3M | /scnx-vs-pcsa → |
| ADXN Addex Therapeutics Ltd | D | 48/100 | — | — | — | +5.46% | $5.3M | /adxn-vs-pcsa → |
| LGVN Longeveron Inc. (Class A) | E | 27/100 | — | 67.0% | -35.0% | -4.57% | $5.3M | /lgvn-vs-pcsa → |
| GELS Gelteq Limited | D+ | 54/100 | — | — | — | -3.14% | $5.2M | /gels-vs-pcsa → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Processa Pharmaceuticals Inc. (PCSA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$13.6M, operating cash flow of -$11.4M, and free cash flow of -$11.4M (-1.2% YoY). On the balance sheet, PCSA closed FY2025 with $7.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$13.6M | -$11.4M | -$11.4M | $7.8M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$11.8M | -$11.2M | -$11.2M | $3.2M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$11.1M | -$8.1M | -$8.1M | — | — |
As of 2026-11-03, Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.89 (0.00% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PCSA ranks #494 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PCSA carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SCNX (Scienture Holdings Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and ADXN (Addex Therapeutics Ltd) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $5.3M). Among the 5-stock peer group, PCSA leads on earnings multiple (N/A) while PCSA leads on capital efficiency (-35.0% ROIC).
Per PCSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533743), Processa Pharmaceuticals Inc. generated $0 in revenue, -$13.6M in net income, and -$11.4M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PCSA last traded at $1.89 (0.00% on volume of 25,373 shares), positioning the stock +2.72% above its 50-day simple moving average ($1.84) and -19.23% below its 200-day simple moving average ($2.34). Across its 52-week range of $1.04 to $10.25, PCSA sits at the 9.2% percentile with a 14-day RSI of 55.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.65 to $2.13).
Why PCSA Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, PCSA scores 39 out of 100 and receives a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:
Taken together, the rating frames PCSA as a high-risk, cash-consuming equity where the upside case depends on events outside the current financial profile. Valuation tradeoffs are significant: with a market capitalization of $5.3M and no reported positive earnings, traditional earnings-based valuation is not available in source data. Upside drivers would need to come from pipeline progress and corporate actions rather than current operations.
Processa Pharmaceuticals Inc. is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations. Per the company profile, the market capitalization is listed as $0.0B. Specific product lines, customer base, and revenue model are not available in source data. Per the SEC financials, reported revenue was $0.0M in each of FY 2023, FY 2024, and FY 2025, indicating no reported revenue in the periods provided. Per recent news, the company has announced a pipeline item (a BTK inhibitor, VT-7208) and a merger with Vidya Therapeutics; details beyond these headlines are not available in source data.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-14.0M | $-13.6M | N/A | $-11.4M | $5.5M | N/A |
| FY 2024 | $0.0M | $-12.1M | $-11.8M | N/A | $-11.2M | $1.2M | N/A |
| FY 2023 | $0.0M | $-11.5M | $-11.1M | N/A | $-8.1M | N/A | N/A |
Per the SEC financials, the company reported operating losses and net losses in each period shown, with gross, operating, and net margins all listed at 0% in market data. Per the Roarable RQD rating, ROIC is -35%. The Altman Z-Score of 2.5 and Piotroski F-Score of 2/9 are cited within the forensic balance sheet pillar; the Piotroski score is weak. Debt/Equity is listed as 0.5. Reported cash rose from $1.2M (FY 2024) to $5.5M (FY 2025), while FCF remained negative in every period.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. An investor should note that the pipeline (VT-7208) and the Vidya merger are the company's main external linkages per the news wire, but their supply-chain relationships are not mapped in the provided graph.
Real-time company headlines, analyst actions, and sector developments for Processa Pharmaceuticals Inc. (PCSA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.
Kalkine report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Processa Pharmaceuticals Inc. (PCSA) market action, institutional positioning, and fundamental catalysts.
Welcome to the PCSA (Processa Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on PCSA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Processa Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on PCSA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.89 (52-wk range $1.04 - $10.25), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).